Alkali Metals
NSE: ALKALI · Specialty Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Alkali Metals's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alkali Metals Ltd is an ISO-certified manufacturer specialising in sodium metal derivatives, pyridine derivatives, fine chemicals, and active pharmaceutical ingredients (APIs). The company primarily serves the pharmaceutical sector by providing essential chemical intermediates for bulk drug production.
Business Model
The company generates revenue through the manufacturing and sale of specialised chemical compounds used as building blocks in pharmaceutical synthesis. It operates as a B2B supplier, leveraging its technical expertise in sodium and pyridine chemistry to support bulk drug manufacturers.
Growth Outlook
Growth is driven by the increasing demand for complex chemical intermediates within the pharmaceutical industry. The company continues to focus on its core competencies in picoline-based and cyclic chemicals to maintain its market position.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of key raw materials like sodium and pyridine can significantly impact profit margins.
- Regulatory Compliance. The chemical manufacturing sector is subject to stringent environmental and safety regulations that may increase operational costs.
- Client Concentration. Heavy reliance on the pharmaceutical industry makes the company vulnerable to cyclical downturns or policy shifts within the drug manufacturing sector.
- Operational Hazards. The handling of reactive chemicals like sodium metal poses inherent safety and environmental risks that require continuous investment in risk mitigation.
Start your research today
Unlock AI insights, financials, peers and live data on Alkali Metals and 5,000+ companies — free.
Key Metrics
REVENUE
₹93 Cr
TTM · standalone
NET PROFIT
₹0.57 Cr
TTM · standalone
EPS
₹0.54
TTM · standalone
RETURN ON EQUITY
1.3%
TTM · standalone
P/E
161.3x
Q4 FY26 · standalone
EV/EBITDA
14.9x
Q4 FY26 · standalone
EBITDA MARGIN
8.8%
TTM · standalone
NET PROFIT MARGIN
14.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.4x
Q4 FY26 · standalone
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Alkali MetalsALKALI | ₹103 Cr | 161.30 | 14.88 | 13.0% | 8.8% | 1.3% | 10.9% | -5.0% |
Black Rose IndusBLACKROSE | ₹586 Cr | 19.65 | 13.25 | -0.2% | 12.5% | 17.8% | 23.9% | +10.3% |
Vipul OrganicsVIPULORG | ₹506 Cr | 55.50 | 28.24 | 16.8% | 10.4% | 9.0% | 13.0% | +26.1% |
Plastiblends India LimitedPLASTIBLEN | ₹487 Cr | 11.78 | 6.76 | 5.5% | 9.2% | 9.7% | 12.8% | +4.3% |
Agastya Energy and Infrastructure LimitedSANGINITA | ₹455 Cr | -19.81 | -83.28 | -23.2% | -3.2% | -18.0% | -14.1% | +581.9% |
Aarti SurfactantAARTISURF | ₹449 Cr | 22.93 | 9.64 | 25.2% | 6.1% | 7.7% | 12.4% | +7.3% |
As of Q4 FY26
Financials
Alkali Metals
NSE: ALKALI · Specialty Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Alkali Metals's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alkali Metals Ltd is an ISO-certified manufacturer specialising in sodium metal derivatives, pyridine derivatives, fine chemicals, and active pharmaceutical ingredients (APIs). The company primarily serves the pharmaceutical sector by providing essential chemical intermediates for bulk drug production.
Business Model
The company generates revenue through the manufacturing and sale of specialised chemical compounds used as building blocks in pharmaceutical synthesis. It operates as a B2B supplier, leveraging its technical expertise in sodium and pyridine chemistry to support bulk drug manufacturers.
Growth Outlook
Growth is driven by the increasing demand for complex chemical intermediates within the pharmaceutical industry. The company continues to focus on its core competencies in picoline-based and cyclic chemicals to maintain its market position.
Key Risks
- Raw Material Price Volatility. Fluctuations in the cost of key raw materials like sodium and pyridine can significantly impact profit margins.
- Regulatory Compliance. The chemical manufacturing sector is subject to stringent environmental and safety regulations that may increase operational costs.
- Client Concentration. Heavy reliance on the pharmaceutical industry makes the company vulnerable to cyclical downturns or policy shifts within the drug manufacturing sector.
- Operational Hazards. The handling of reactive chemicals like sodium metal poses inherent safety and environmental risks that require continuous investment in risk mitigation.
Start your research today
Unlock AI insights, financials, peers and live data on Alkali Metals and 5,000+ companies — free.
Key Metrics
REVENUE
₹93 Cr
TTM · standalone
NET PROFIT
₹0.57 Cr
TTM · standalone
EPS
₹0.54
TTM · standalone
RETURN ON EQUITY
1.3%
TTM · standalone
P/E
161.3x
Q4 FY26 · standalone
EV/EBITDA
14.9x
Q4 FY26 · standalone
EBITDA MARGIN
8.8%
TTM · standalone
NET PROFIT MARGIN
14.0%
Q4 FY26 · standalone
DEBT TO EQUITY
0.4x
Q4 FY26 · standalone
Peers · Specialty Chemicals
As of Q4 FY26